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Abstract
 
Signals generated through CD28–B7 and CD40 ligand (CD40L)–CD40 interactions have been
shown to be crucial for the induction of long-term allograft survivability. We have recently
demonstrated that humanized anti-CD40L (hu5C8) prevents rejection of mismatched renal al-
lografts in primates. To investigate potential mechanisms of CD40L–induced allograft accep-
 
tance, we coimmobilized hu5C8 with suboptimal amounts of anti-CD3 to stimulate CD4
 
1
 
 T
cells. We now report that anti-CD3/CD40L costimulation results in CD28-independent acti-
vation and subsequent deletion of resting T cells. Coligation of CD3 and CD40L increased ex-
pression of CD69, CD25, and CD54 on CD4
 
1 
 
T cells. We also found that costimulation with
 
anti-CD3/CD40L resulted in enhanced production of interleukin (IL)-10, interferon 
 
g
 
, and
tumor necrosis factor 
 
a
 
 but not IL-2 or IL-6. Interestingly, after several days, anti-CD3/
CD40L–mediated activation was followed by apoptosis in a significant population of cells.
Consistent with that observation, anti-CD3/CD40L did not enhance the antiapoptotic pro-
teins Bcl-2 and Bcl-xL. Further, the addition of CD28 at 24 h failed to rescue those cells in-
duced to die after costimulation with anti-CD3/CD40L. Together, these data suggest that the
 
graft-sparing effect of hu5C8 in vivo
 
 
 
may result in part from early and direct effects on CD4
 
1
 
T cells, including a vigorous induction of immunomodulatory cytokines and/or apoptosis of
allograft-specific T cells.
Key words: costimulatory molecules • T lymphocytes • transplantation • cytokines • apoptosis
 
Introduction
 
Binding of CD40 with its counterreceptor, CD40 ligand
(CD40L), acts on APCs and T cells in a bidirectional fash-
ion, mediating both humoral and cellular immune re-
sponses. In B cells, cross-linking CD40 drives differentia-
tion, proliferation, and isotype switching while preventing
B cell apoptosis (1). In T cells, CD40L expression is rapidly
but transiently induced after CD3 stimulation (2–4). Much
evidence suggests that CD40L is an important regulator of
T cell responses. In CD40L-deficient mice, it has been
demonstrated that antigen-specific T cell responses were
impaired and that therefore the expression of CD40L on T
cells was required for the in vivo
 
 
 
priming of CD4
 
1
 
 cells (5,
6). Enhancement of T cell responses by CD40L results par-
tially from upregulation of CD80 and CD86 on the APCs
(7, 8). CD40L has been shown to induce proliferation and
cytokine production in small resting human T cells stimu-
lated with soluble anti-CD3 and CD40-transfected mouse
P815 cells (9, 10) and to directly provide signals to
CD40L
 
1
 
 Jurkat T cells, which results in neutral sphingo-
 
myelinase, c-Jun NH
 
2
 
-terminal kinase (JNK), and p38 mi-
togen-activated protein (MAP) kinase induction (11, 12).
It is becoming clear that peripheral tolerance to allografts
is dependent on the interplay of several costimulatory mol-
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ecules that work cooperatively to regulate effector func-
tions (13, 14). Acceptance of alloantigens can be induced in
adult animals by injection of anti-CD40L antibodies or
CD40-deficient B cells (15). Recent reports have shown
that antibodies to CD40L in combination with CTL-asso-
ciated antigen 4–Ig (CTLA4-Ig)
 
1
 
 or donor-specific T cells
could induce prolonged rejection-free survival to islet,
heart, and skin allografts in mice (16–18). Anti-CD40L
treatment has also been shown to preserve kidney function
in mice with established nephritis (19). We have effectively
used a strategy to block costimulatory signals to prevent re-
jection of primate renal allografts using CTLA4-Ig and the
anti-CD40L mAb hu5C8. Whereas costimulation blockade
with CTLA4-Ig alone was unsuccessful, anti-CD40L treat-
ment resulted in sustained graft survival (20). More re-
cently, we have shown that anti-CD40L (hu5C8) alone
prevented acute rejection and increased kidney allograft
survival in nonhuman primates. We also demonstrated that
additional immunosuppressants abrogated the affects medi-
ated by hu5C8 (21).
Here, we test the functional effects of the anti-CD40L
mAb hu5C8 on purified human CD4
 
1
 
 T cells when coim-
mobilized with anti-CD3. We compared these findings
with results generated in cultures of CD4
 
1
 
 T cells stimu-
lated with anti-CD3 and CD32
 
1
 
CD40
 
1
 
 transfectants. Our
data demonstrate that CD40L can costimulate CD4
 
1
 
 T
cells in the absence of CD28, causing transient thymidine
incorporation and activation. CD40L-mediated costimula-
tion was characterized by an increase in T cell activation
and adhesion antigens and enhanced production of IFN-
 
g
 
,
TNF-
 
a
 
, and IL-10. However, in anti-CD3/CD40L–stim-
ulated cultures, apoptosis occurred within 3 d in many
cells. The paradox of first allowing and then failing to sus-
tain T cell proliferation may suggest a critical role for
CD40L in driving short-term T cell effector responses that
do not lead to the development of memory.
 
Materials and Methods
 
Cells and Antibodies.
 
Freshly isolated PBLs were separated by
Percoll (Amersham Pharmacia Biotech) gradient centrifugation
from leukopacks obtained by apheresis from healthy donors.
CD4
 
1
 
 T cells were purified by negative selection. Hu5C8, an
anti-CD40L mAb, was a gift from Dr. Linda Burkly (Biogen,
Inc., Cambridge, MA). Anti-CD3 huOKT3 (human IgG1;
Ortho Biotech) was a gift of Dr. Jeffrey Bluestone (University of
Chicago, Chicago, IL); anti-CD28 9.3 (mouse IgG2a), anti–
monomorphic HLA class I mAb W6/32 (mouse IgG2a; Ameri-
can Type Culture Collection), anti–class II mAb 2.06 (mouse
IgG1; American Type Culture Collection), and anti-glycophorin
A 10FTMC (IgG1; American Type Culture Collection) served as
binding and nonbinding controls. Humanized anti-CD80 (1F1,
IgG1) and anti-CD86 (3D1, IgG2a) were gifts from Dr. Gary
Gray (Genetics Institute, Cambridge, MA). The following anti-
 
bodies were used to immunophenotype T cells: anti-CD4 (clone
SK3, IgG1; Becton Dickinson), anti-CD69–PE (clone L78,
IgG1; Becton Dickinson), anti-CD25–PE (clone 2A3, IgG1;
Becton Dickinson), and anti-CD54 (IgG2a; Immunotech).
 
Bead Preparation.
 
Anti-CD3 and control or anti-CD40L
mAbs were covalently attached to 0.5-
 
m
 
m polyurethane-coated
tosyl-activated Dynabeads
 
®
 
 (Dynal) according to the manufac-
turer’s instructions. The bead to cell ratio used in cultures was 3:1.
Beads were prepared with a constant amount of anti-CD3 anti-
body representing 12.5% of bound protein, and with control,
anti-CD28, or anti-CD40L mAb to make up the remaining
87.5%.
 
CD40
 
1
 
 Transfectants.
 
A full-length cDNA for human (h)CD40
was generated from Raji RNA using primers flanked by KpnI
and NotI sites. This cDNA was cloned into pcDNA 3.1 (Invitro-
gen), digested with ScaI, and electroporated into CD32
 
1
 
 L cells
(a gift of G. Delespesse, University of Montreal, Montreal, Can-
ada) using standard procedures to create CD32
 
1
 
CD40
 
1
 
 L cells.
Stable transfectants were generated by staining CD32-Fc
 
g
 
–
treated cells with an mAb against CD40 (Becton Dickinson) and
then performing multiple sterile sorts using an EPICS
 
®
 
 ELITE
ESP cell sorter (Coulter). CD86-transfected CD32
 
1
 
 L cells were
a gift of G. Delespesse.
 
T Cell Function Assay.
 
CD4
 
1
 
 T cells were plated in 96-well
flat-bottomed microtiter plates at a density of 10
 
6
 
 cells/ml in a to-
tal volume of 200 
 
m
 
l RPMI (GIBCO BRL). Proliferation was
measured after a pulse with 1 
 
m
 
Ci of [
 
3
 
H]thymidine. Cytokine
concentrations in cell-free supernatants were assayed by ELISA
(R&D Systems). Apoptosis was analyzed using a modified termi-
nal deoxynucleotidyl transferase–mediated dUTP nick end label-
ing (TUNEL)-based procedure (22).
 
PCR-based Liquid Hybridization Assay.
 
Steady state cytokine
mRNA levels were assayed by semiquantitative reverse tran-
scriptase (RT)-PCR–based liquid hybridization using the follow-
ing primers and probes as described previously (23). RT-gener-
ated PCR products were diluted as indicated in the figure
legends. To ensure that the PCR reactions were performed in
the linear range of the assay, a twofold dilution of the RT prod-
uct was amplified at 95
 
8
 
C for 0.5 min, 55
 
8
 
C for 0.5 min, and
72
 
8
 
C for 1.5 min for 25 cycles with the primers listed below. Liq-
uid hybridization of the PCR products was conducted as re-
ported previously. In brief, 20,000 counts of the probes listed be-
low were hybridized in 30-
 
m
 
l reactions. After hybridization,
samples were loaded into 10% acrylamide gels, run at 140 V for
75 min, and then exposed to a PhosphorImager
 
®
 
 screen (Molec-
ular Probes). Assays were validated by determining whether two-
fold differences in signal strength could be detected. Primers were
as follows: for IL-2 (sense) 5
 
9
 
-CAA CTC CTG TCT TGC ATT
GC-3
 
9
 
, (antisense) 5
 
9
 
-TTC TGT GGC CTT CTT GGG-3
 
9
 
,
(probe) 5
 
9
 
-ACA AGA ATC CCA AAC TCA CCA GG-3
 
9
 
; for
IL-6 (sense) 5
 
9
 
-AAG ATT CCA AAG ATG TAG CC-3
 
9
 
, (anti-
sense) 5
 
9
 
-CCT CAA ACT CCA AAA GAC CA-3
 
9
 
, (probe) 5
 
9
 
-
GAG AAA GGA GAC ATG TAA C-3
 
9
 
; for IL-10 (sense) 5
 
9
 
-
TTG CCT GGT CCT CCT GAC TG-3
 
9
 
, (antisense) 5
 
9
 
-GAT
GTC TGG GTC TTG GTT CT-3
 
9
 
, (probe) 5
 
9
 
-ATG AAG
GAT CAG CTG GAC AA-3
 
9
 
; for IFN-
 
g 
 
(sense) 5
 
9
 
-TGC AGG
TCA TTC AGA TGT AG-3
 
9
 
, (antisense) 5
 
9
 
-TCT CGT TTC
TTT TTG TTG CT-3
 
9
 
, (probe) 5
 
9
 
-GGA GAC CAT CAA
GGA AGA CA-3
 
9
 
; for glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) (sense) 5
 
9
 
-ATG GGG AAG GTG AAG GTC
GGA GTC AAC GGA-3
 
9
 
, (antisense) 5
 
9
 
-AGG GGG CAG
AGA TGA TGA CCC TTT TGG CTC-3
 
9
 
, (probe) 5
 
9
 
-TCG
CTC CTG GAA GAT GGT GAT GGG ATT TCC-3
 
9
 
.
 
1
 
Abbreviations used in this paper:
 
 CSA, cyclosporin A; CTLA4-Ig, CTL-
associated antigen 4–Ig; hu5C8, humanized anti-CD40L mAb clone 5C8;
RT, reverse transcriptase; TUNEL, terminal deoxynucleotidyl trans-
ferase–mediated dUTP nick end-labeling. 
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Immunoblotting.
 
Bcl-x and Bcl-2 (PharMingen) proteins
were immunoprecipitated and Western blotted as described pre-
viously (22). Bcl-x antibodies were a gift from Craig Thompson
(University of Chicago, Chicago, IL).
 
Results and Discussion
 
Anti-CD3/CD40L Stimulation Provides a Costimulatory
Signal to Resting Human CD4
 
1
 
 T Cells.
 
CD40L is rapidly
induced on the surface of T cells after CD3 ligation (3, 4).
Given our published findings (20, 21) demonstrating the
dramatic ability of anti-CD40L to prolong primate kidney
allograft survival, we have examined the costimulatory
effects of the hu5C8 antibody on purified CD4
 
1
 
 T cell
function by binding suboptimal amounts of anti-CD3 anti-
bodies in combination with anti-CD40L on 5-
 
m
 
m micro-
spheres. As shown in Fig. 1 A, we compared thymidine in-
corporation in highly enriched (
 
.
 
95%) CD4
 
1
 
 T cells
stimulated with anti-CD3/CD40L to responses in cultures
stimulated by equivalent amounts of anti-CD3 plus anti-
bodies against either MHC class I, MHC class II, or CD28.
In addition, some experiments included beads prepared
with anti-CD3 plus antiglycophorin as a nonbinding con-
trol antibody. We saw insignificant thymidine incorpora-
tion in CD4
 
1
 
 T cell cultures stimulated by anti-CD3/
glycophorin– or by anti-CD3/MHC–coated beads. As an-
ticipated, stimulation with anti-CD3/CD28–coated beads
led to robust proliferative responses. Surprisingly, anti-
CD3/CD40L–coated beads also induced significant CD4
 
1
 
T cell thymidine incorporation. Both humanized and non-
humanized 5C8 (anti-CD40L) performed similarly in this
assay. Our result is in contrast to earlier work that demon-
strated no anti-CD3/CD40L proliferative responses in pu-
rified CD4
 
1
 
 T cells but a dramatic increase in anti-CD3/
CD28 proliferative responses after the addition of anti-
CD40L (24). In further contrast, we found that adding
anti-CD28 to anti-CD3/CD40L–coated beads led to only
a modest increase in thymidine incorporation, especially
when compared with the effect of adding anti-CD28 to
anti-CD3/MHC class I–coated beads. These differences
could be attributed to our use of antibodies presented to T
cells on three-dimensional beads, as opposed to plate-
bound antibodies. Alternatively, it is also possible that there
are special agonistic properties of the hu5C8 mAb that are
not found with other anti-CD40L reagents.
Both CD54 and CD44H are rapidly induced by CD40L
ligation (25, 26). After CD40L ligation, the role of these
molecules is not one of costimulation but of adhesion, pre-
sumably to amplify and sustain signals through the TCR.
To further test the effects of anti-CD3/CD40L beads on
CD4
 
1
 
 T cell activation, we measured the expression of
several T cell activation and adhesion molecules (Fig. 1 B).
24 h after anti-CD3/CD40L–mediated activation, the early
activation markers CD69, CD25, and CD54 were all ex-
pressed at levels comparable to those seen in anti-CD3/
CD28–stimulated cells. The intensity of anti-CD3/
CD40L–induced responses at 24 h was surprising; there-
fore, we determined the kinetics of CD25, CD54, and
CD69 expression (Table I). Cells were stimulated optimally
with anti-CD3/CD28–coated, with anti-CD3/CD40L–
coated beads, or with control beads that either bound
(anti–MHC I) or did not bind (glycophorin) T cells. Inter-
esting, our results showed that CD3/CD40L coligation had
the capacity to induce an early activation response in T
cells, resulting in significant increases in the expression of
these markers. However, the duration of anti-CD3/
CD40L responses decreased markedly by 48 h. These re-
sults are comparable to the anti-CD3/CD40L–mediated
thymidine incorporation we had previously measured (Fig.
1) and suggest that coligation of CD3 and CD40L on T
cells alone does not lead to sustained activation.
 
CD28-independent Effects after Anti-CD3/CD40L Costim-
ulation.
 
CD28 is necessary for sustained antigen-depen-
dent T cell proliferation (27). Anti-CD28 Fab fragments
Figure 1. Anti-CD3/CD40L stimulation provides a costimulatory sig-
nal for purified human CD41 T cells. (A) Purified CD41 T cells were cul-
tured with beads coated with anti-CD3 antibody in combination with
anti-CD40L, anti-CD28, or control MHC class I, MHC class II, or glyco-
phorin (Gly.) antibodies at a 3:1 cell to bead ratio for 54 h. Cells were also
cultured with anti-CD3/CD28–coated beads in combination with either
MHC class I or CD40L mAbs. Cultures were pulsed and harvested after an
additional 18 h. Data represent the mean 6 SEM from three separate as-
says. (B) Expression of activation and adhesion molecules in purified
CD41 T cells after 24-h stimulation with either anti-CD3/MHC class I
(control), anti-CD3/CD40L, or anti-CD3/CD28. Representative fluores-
cence histograms of isotype control reagents (thin lines) and either CD69,
CD25, or intracellular adhesion molecule (ICAM) (thick lines) are shown.
Histograms were first gated on live CD4-FITC–stained cells. 
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and antibodies to CD80 and CD86 block T cell prolifera-
tion induced by plant lectins or anti-CD3 (28). To test
whether the CD40L receptor–induced costimulatory ef-
fects were CD28 dependent, we treated anti-CD3/
CD40L–stimulated cultures with agents that prevent
CD28-mediated responses. As shown in Fig. 2, CD40L–
induced T cell activation is largely CD28 and CD80/
 
CD86 independent, as judged by the relative inability of
these reagents to block T cell thymidine incorporation. In
separate reagent control experiments, we found that the
CD28 Fab fragments and CD80/CD86 antibodies had re-
tained full inhibitory activity (data not shown). Costimula-
tion through CD28 drives cyclosporin A (CSA)-indepen-
dent T cell proliferation, cytotoxic activity, and the increased
production of cytokines including IL-2, IFN-
 
g
 
, and TNF-
 
a
 
through both de novo synthesis and mRNA stabilization
(29). CSA, which inhibits calcineurin activation through
the TCR (30), has been shown to block induction of T cell
apoptosis (31). In Fig. 2, we found that, unlike CD28 (32),
CD40L-induced thymidine incorporation was sensitive to
CSA treatment in a dose-dependent fashion. Subsequently,
we determined that CD40L expression decreased on hu-
man CD41 T cells as CSA concentrations increased (data
not shown). This observation is consistent with previous
studies (33) and suggests that concurrent treatment of trans-
plant recipients with CSA and hu5C8 could reduce the ef-
fectiveness of events mediated through CD40L. Finally,
our results demonstrate that the addition of exogenous IL-2
further augmented the thymidine incorporation induced by
anti-CD3/CD40L–coated beads (Fig. 2). This is also con-
sistent with the notion that anti-CD3/CD40L– and anti-
CD3/CD28–stimulated T cell activation are distinct, as the
addition of exogenous IL-2 did not further stimulate anti-
CD3/CD28–stimulated T cells (data not shown).
Measurement of Cytokine mRNA and Protein Levels in Anti-
CD3/CD40L–stimulated CD41 T Cells. Experiments in
CD40L-deficient and CD40-deficient mice have shown
that CD40–CD40L interactions play an important role in
regulating cytokine responses (34, 35). Ligation of CD40L
on T cells is crucial for the T cell contact–dependent sig-
naling to induce nitric oxide and cytokine production (36),
indicating that CD40L may be involved in inhibiting T cell
activation responses. While most available information in-
dicates that CD40L regulates cytokine secretion indirectly
through its effects on APCs, the ability of CD40L to in-
duce CD41 T cell activation suggested that CD40L might
have direct effects on T cell cytokine secretion. To test this
possibility, we assayed cytokine levels in cells stimulated
with anti-CD3/CD40L–coated beads compared with anti-
CD3/CD28–coated beads or with beads coated with anti-
Figure 2. Specific effects after anti-CD3/
CD40L costimulation. (A) Purified cells were
cultured for 72 h with anti-CD3/CD40L–
coated beads in combination with titrated
amounts of CSA, anti-CD28 (9.3) Fab frag-
ments, anti–B7-1 and anti–B7-2 antibodies,
or rIL-2 (300 U/ml). Proliferation was mea-
sured as indicated in the legend to Fig. 1.
Table I. Immunophenotyping Kinetics on Stimulated CD41
T Cells
Stimulation Time % CD25 % CD54 % CD69
h 6SEM 6SEM 6SEM
0 6.6 1.9 15.2
CD3/glycophorin 12 4.0 6 0.4 0.7 6 0.1 20.8 6 5.3
24 6.7 6 0.4 0.9 6 0.1 23.9 6 6.1
48 7.1 6 0.2 0.8 6 0.4 25.4 6 6.7
72 4.8 6 0.2 1.3 6 0.5 23.3 6 5.5
96 3.9 6 0.5 0.9 6 0.2 17.7 6 5.6
CD3/MHC I 12 2.8 6 0.1 1.2 6 0.1 12.6 6 5.3
24 3.7 6 0.4 2.2 6 0.4 12.3 6 4.0
48 7.6 6 0.8 1.6 6 0.3 14.5 6 2.3
72 6.8 6 1.0 1.6 6 0.4 13.4 6 6.2
96 4.4 6 1.2 1.2 6 0.2 12.9 6 5.2
CD3/CD40L 12 14.9 6 3.5 3.7 6 2.0 57.3 6 5.0
24 48.3 6 7.1 21.5 6 4.0 68.4 6 7.1
48 31.9 6 4.3 11.0 6 2.3 56.0 6 3.8
72 24.4 6 4.5 7.1 6 1.2 39.2 6 7.5
96 17.2 6 3.2 4.1 6 0.8 29.8 6 1.3
CD3/CD28 12 69.1 6 1.0 14.4 6 0.5 78.1 6 2.6
24 83.3 6 2.5 31.1 6 4.2 84.8 6 1.5
48 92.0 6 0.7 45.3 6 5.4 94.5 6 0.5
72 95.6 6 0.2 62.0 6 5.0 91.4 6 1.0
96 97.3 6 1.2 44.5 6 3.5 86.2 6 1.3
Cells were stained as described in Materials and Methods and labeled
with the indicated mAbs. Percent frequencies are shown for 5 3 104
lymphocytes first gated as CD4-PE1. SEM shown from three to four
separate donors.655 Blair et al.
CD3/MHC class I mAbs (Fig. 3). Using first a semiquanti-
tative RT-PCR–based assay, we measured IL-2, IL-6, IL-10,
and IFN-g mRNA transcripts in cells activated for 24 h
(Fig. 3 A). We found high levels of IL-10 and IFN-g tran-
scripts induced in CD41 T cell cultures stimulated with
anti-CD3/CD40L–coated beads and low or undetectable
levels of IL-2 and IL-6 transcripts. In contrast, in cells sim-
ulated with anti-CD3/CD28–coated beads, we identified
high amounts of IL-2, IFN-g, IL-6, and IL-10 transcripts.
When cultures were examined earlier (after 4–8 h of cul-
ture), high levels of TNF-a transcripts were seen in both
CD3/CD40L- and CD3/CD28-stimulated cultures while
we continued to observe that IL-2 transcripts were re-
stricted to the CD3/CD28-stimulated cultures (data not
shown).
We also examined the accumulation of cytokines in the
supernatants of CD41 cells by ELISA (Fig. 3 B). These re-
sults confirmed the large (.100-fold) difference in IL-2
secretion between anti-CD3/CD28– and anti-CD3/CD40L–
stimulated cultures. In marked contrast, the anti-CD3/
CD40L–stimulated cultures had high and sustained levels of
IL-10 that were equivalent to those found in CD3/CD28-
stimulated cultures. The increase in IL-10 was specific to
anti-CD40L, as cultures stimulated with the control CD3/
MHC class I beads did not accumulate IL-10. Levels of
TNF-a and IFN-g were also elevated in the supernatants
from the CD3/CD40L-stimulated cultures, demonstrating
that both Th1- and Th2-type cytokines had been secreted.
CD321CD401 Transfectants Induce CD41 T Cell Prolifer-
ation and Production of Immunomodulatory Cytokines, but Not
IL-2. To determine whether the cytokine profiles we
found in anti-CD3/CD40L bead–stimulated cells were
unique to this model system and/or to the anti-CD40L
mAb 5C8, we generated CD401 transfectants by elec-
troporation of human CD40 into CD321 mouse L cells
(Table II). The CD32 receptor transfected previously in
these cells bound soluble anti-CD3 (huOKT3). We found
that upon addition of anti-CD3, CD401 L cells were po-
tent stimulators of purified populations of CD41 T cells,
leading to activation responses similar to those results gen-
erated in our studies with anti-CD3/CD154–coated beads.
In these experiments, we measured cell proliferation, and
IL-2, IL-10, IFN-g, and TNF-a production. Responses
were compared against CD86-transfected CD321 L cells
and CD321 L cells that bound anti-CD3. As evident in Ta-
Figure 3. Measurement of cytokine mRNA and protein levels in stimulated CD41 T cells. (A) Total RNA was extracted from cells cultured as indi-
cated and a semiquantitative RT-PCR–based assay using liquid hybridization was performed on 2.5, 5, or 10 ml of RT products. Samples that lacked RT
(–) were included for each condition. Results represent at least three separate assays. (B) Kinetics of cytokine secretion (in pg/ml) after stimulation. Cell-
free supernatants from cells cultured as indicated were assayed by ELISA for IL-2, TNF-a, IFN-g, and IL-10.
Table II. Cytokine Expression at 72 h in Supernatants from 
Stimulated CD41 T Cells
Stimulation* IL-2 IL-10 IFN-g TNF-a
Thymidine
incorporation
CD401 L cells ,31.2 0 10 ,15.2 2,597
L cells 1 
anti-CD3 42 163 333 ,15.2 19,201
CD401 L cells 1 
anti-CD3 63 494 8,936 1,471 31,308
B7-21 L cells 1
anti-CD3 5,418 191 7,388 7,286 21,022
Supernatants were collected from stimulated cells after 72 h culture, and
IL-2, IL-10, IFN-g, and TNF-a production were measured by ELISA
as described in Materials and Methods. Results (in pg/ml) are a
representation from two to three separate assays using different donors.
*CD41 T cells were plated in 24-well culture dishes over CD321
mouse L cells that were either not transfected, or were transfected with
human CD40 or CD86. Where noted, anti-CD3 (OKT3) was added at
a concentration of 200 ng/ml. Previously, we had optimized anti-
CD3–mediated effects in L cells by titrating concentrations.656 CD40L-mediated T Cell Regulation
ble II, we saw significant thymidine incorporation in anti-
CD3–treated CD401 L cells that was comparable to levels
seen in CD80 and CD86 transfectants and almost double
the levels in L cells treated with anti-CD3 alone. Of inter-
est, we noted that while anti-CD3–treated CD401 L cells
did not produce IL-2, significant amounts of IL-10 and
IFN-g were made. These results compliment what we
have documented above using anti-CD3/CD40L–coated
microspheres and suggest that stimulation through CD40–
CD40L without concurrent ligation through CD28 has a
direct effect on CD41 T cells that results in the upregula-
tion of the immunosuppressive cytokines IL-10, TNF-a,
and IFN-g, but not IL-2.
In both anti-CD3/CD40L–ligated and anti-CD3
CD401–transfected CD41 T cells, we noted significant IL-
10 production. IL-10 is a potent immunosuppressive cy-
tokine that acts to prevent autoimmune disease onset (insu-
lin-dependent diabetes mellitus) in nonobese diabetic
(NOD) mice (37, 38). Others have shown that chronic ac-
tivation of both human and murine CD41 T cells in the
presence of IL-10 gives rise to CD41 T cells with low pro-
liferative capacity that produce high levels of IL-10 and low
levels of IL-2. These antigen-specific T cells suppress the
proliferation of CD41 T cells in response to antigen (39).
We speculate that CD3/CD40L-activated CD41 T cells
may result in the unique cytokine production profile de-
scribed, and that these cytokines may contribute to the
overall immunosuppressive effects of CD40L mAb ob-
served in vivo.
The production of IL-2 by activated T cells is an auto-
crine signal that leads to T cell proliferation and the devel-
opment of effector functions, and thus is important in the
understanding of costimulator regulators such as CD40L in
T cell responses. Interestingly, unlike earlier reports (9, 10),
which used the same transfected mouse cell line, we found
that in both our bead and CD40-transfected cell models
costimulation through anti-CD3/CD40L did not lead to
an increase in IL-2. In fact, levels of IL-2 induced by anti-
CD3/CD40L stimulation were similar to levels seen in
anti-CD3/MHC class I–stimulated cells and dramatically
lower than levels seen in anti-CD3/CD28 bead cultures or
B7-2–transfected L cells (Fig. 3 B, and Table II). These re-
sults clearly demonstrate that although CD25 is upregulated
on the surface of anti-CD3/CD40L–stimulated human
CD41 T cells, little or no IL-2 is actually produced after
anti-CD3/CD40L ligation. We cannot rule out the possi-
bility that small amounts of IL-2 induced by CD40L co-
stimulation may have been rapidly reincorporated by the
cultured cells. Our findings are supported by other studies.
Johnson-Leger et al.  demonstrated that CD3-primed
CD40L1 T cells were incompetent helper cells because
they secreted insufficient IL-2 (40). They proposed that T
cells must first encounter antigen in conjunction with
CD28–B7 interactions before CD40L is stabilized on the
surface and IL-2 is produced (41). Additionally, Gray and
colleagues used CD40L knockout mice to show that
CD40L delivers signals to T cells that enhanced the matu-
ration of IFN-g and played a role in the development of
Th2 cells to optimize IL-4 secretion. However, they found
that CD40L ligation had no effect on IL-2 production (42).
In many regards, our results are similar to those seen by
Cayabyab et al. (9) and Peng et al. (10). For instance, they
(as we) measured appreciable levels of IL-10 and IFN-g af-
ter culture of T cells with anti-CD3 and CD401 transfec-
tants. Within the transfected mouse cell system, however,
the impact of additional costimulatory pathways cannot be
ruled out. For instance, recently an additional and novel
homologue of CD80/CD86 was discovered that is induced
by TNF-a (43). Further, unlike previous work, we used
either purified CD41 T cells that were stimulated by anti-
CD3/CD40L on three-dimensional beads or anti-CD3–
treated CD321CD401 L cells, both of which allowed close
proximity of the coligated signals. Overall, these data
strongly suggest that although signals through CD3 and
CD40L are sufficient to induce short-term proliferation,
they are inadequate to drive IL-2 production and cell cycle
progression.
Effects of Anti-CD3/CD40L Costimulation on Apoptosis
and Expression of Cell Survival Proteins. Programmed cell
death is an important mediator of homeostasis within the
immune system. To test whether engagement of CD40L
might enhance the probability of apoptosis, we first mea-
sured viability kinetics using trypan blue exclusion. Consis-
tent with our hypothesis, cell viability plummeted to
,60% by 144 h (Fig. 4 A) after anti-CD3/CD40L stimula-
tion. In comparison, anti-CD3/CD28–stimulated cultures
maintained .95% viability. To test whether CD41 T cells
were dying via apoptosis, we analyzed DNA fragmentation
using the TUNEL assay (Fig. 4 B). Compared with anti-
CD3/MHC class I–treated (,6%) or anti-CD3/CD28–
treated cultures (,3%), high levels of apoptosis were evi-
dent at 72 h in anti-CD3/CD40L–coligated cultures
(18%). To test whether apoptosis was mediated by Fas or in
an autocrine fashion by TNF-a secretion, we treated anti-
CD3/CD40L–stimulated cultures with neutralizing anti-
bodies to FasL or TNF-a (data not shown). Treatment
with these neutralizing antibodies did not appreciatively
decrease levels of anti-CD3/CD40L–induced apoptosis,
suggesting an independent mechanism of death. As CD28-
mediated costimulation is known to stimulate production
of the cell survival protein Bcl-xL within T cells (44), we
assayed anti-CD3/CD40L–stimulated T cells to see if a
failure to induce Bcl-xL might correlate with the apoptosis
we had observed. Consistent with the increased apoptosis
observed in anti-CD3/CD40L–stimulated T cells, using
immunoprecipitation and Western blotting we found a
complete lack of Bcl-xL (Fig. 4 C). In contrast, CD41 T
cells exhibited high levels of Bcl-xL after stimulation with
anti-CD3/CD28 or with anti-CD3/B7-2–Ig. We saw only
minor differences in Bcl-2 expression when CD28 and
CD40L-costimulated T cells were assayed (Fig. 4 C). It is
likely that the failure to enhance Bcl-xL in an environment
where IL-2 was limited could result in significant apoptosis
in these cultures.
CD28 Fails to Rescue CD41 T Cells from Apoptosis after
Anti-CD3/CD40L Coligation. While T cell costimula-657 Blair et al.
tory molecules can work synergistically, fundamental dif-
ferences exist among these molecules in their capacity to
regulate T cell responses (45). To test whether CD28 liga-
tion could reverse CD40L-induced apoptosis, we analyzed
the kinetics of apoptosis among CD41 T cells after the ad-
dition of beads containing anti-CD3/CD28 in cultures that
were previously either unstimulated or stimulated with
anti-CD3/CD40L (Fig. 5). Apoptosis was measured 24 h
after restimulation of cultured cells. Interestingly, we found
that even short culture (12 h) with anti-CD3/CD40L
induced considerable apoptosis upon restimulation with
anti-CD3/CD28 24 h later. Conversely, relatively little ap-
optosis was seen in unstimulated cultures restimulated with
anti-CD3/CD28. In all cases, anti-CD3/CD28 failed to
decrease apoptosis in cells previously stimulated with anti-
CD3/CD40L.
Our results point to an early and important role for
CD40L in the modulation of T cell responses. Others have
shown that CD40L expression is transient, and that the re-
ceptor is rapidly internalized after binding CD40 (46). Re-
cently, it has been shown that CD40L is specifically regu-
lated at the level of mRNA stability and that this regulation
is not influenced by anti-CD3/CD28 costimulation (47,
48). Our in vivo findings show that the effects of hu5C8
are not solely mediated through the upregulation of
CD80/CD86, as, in a kidney allograft transplantation
model, blocking anti-B7 mAbs did not yield similar results
as those evident after treatment with hu5C8. Additionally,
anti-CD80/CD86 mAbs act synergistically with hu5C8.
This implies that hu5C8 imparts effects on transplanted
grafts apart from B7 and therefore CD28-induced events
(our unpublished data). 
In this study, we have demonstrated that ligation of
CD40L using the anti-CD40L mAb hu5C8 leads to spe-
cific CD28-independent short-term CD41 T cell activa-
tion. However, anti-CD3/CD40L–mediated activation is
aborted due to the enhanced production of immunomodu-
latory cytokines. Ultimately, this resulted in CD41 T cell
apoptosis consequent to the failure to induce IL-2, Bcl-2,
or Bcl-xL expression. We believe that these in vitro results
could point to a mechanism by which hu5C8 is working in
vivo  within our primate kidney allograft transplantation
model. Others have recently highlighted the importance of
apoptosis in the induction of long-term graft survivability
Figure 5. CD28 fails to rescue CD41 T cells from apop-
tosis after anti-CD3/CD40L coligation. Purified CD41 T
cells were initially cultured at 106 cells/ml with or without
(open triangles) anti-CD3/CD28–coated (filled squares) or
anti-CD3/CD40L–coated (circles) microspheres at a cell to
bead ratio of 3:1. At the times indicated, cultures were split.
In half of the samples the beads were removed, and the cells
were then restimulated with anti-CD3/CD28 beads. Apop-
tosis was measured by TUNEL analysis (as in the legend to
Fig. 3) 24 h after restimulation.
Figure 4. Effects of anti-CD3/CD40L costimulation on apoptosis and
expression of cell survival proteins. (A) Viability kinetics in anti-CD3/
CD40L– and anti-CD3/CD28–stimulated cultures. Trypan blue uptake
was assessed in cell suspensions. (B) Apoptosis in cultured cells was mea-
sured using the TUNEL method to measure dUTP incorporation into
single-strand DNA breaks. CD41 T cells irradiated with 1,000-Gy g rays
24 h previously served as a positive control for the assay. Values represent
the mean 6 SEM from five individual experiments. (C) Expression of
the cell survival gene Bcl-xL and Bcl-2. Protein lysates from 107 cells
stimulated for 72 h were subjected to sequential immunoprecipitation
with a Bcl-xL–specific mAb and immunoblotted with a Bcl-xL rabbit
polyclonal antibody as described.658 CD40L-mediated T Cell Regulation
(49, 50). Li et al. demonstrated that treatments that en-
hance the induction of apoptosis, such as CD28–B7 and
CD40–CD40L blockade or costimulation blockade in con-
junction with rapamycin treatment, promote peripheral al-
lograft tolerance (50). Comparable to our results, anti-
CD3/CD40L responses were blocked upon the addition of
CSA. Wells et al. (49) provided additional support for a
crucial role of apoptosis in transplantation tolerance. In
studies that used Bcl-xL–transgenic and IL-2–deficient
mice, they found that models that contained defective pas-
sive or active T cell apoptotic pathways were resistant to
the induction of transplantation tolerance. Interestingly, the
transplantation tolerance induced in the models presented
in these studies and their previous work did not appear to
depend on Fas-induced apoptosis (51). Similarly, in our
work, a neutralizing mAb against Fas did not diminish the
level of apoptosis that we measured after anti-CD3/CD40L
ligation (data not shown). The mechanism by which co-
stimulation blockage induces apoptosis of alloresponsive T
cells is as yet unknown. It will be important to determine
how current costimulatory regimens influence this process.
Our results imply that CD40L may directly signal down-
stream pathways in T cells. This is supported by data that
indicate that the cytoplasmic domain of human and mouse
CD40L is 82% identical (52) and contains structural ele-
ments that are functionally important (46). Aglycosylated
hu5C8, which is unable to cross-link CD40L on the sur-
face of T cells, does not prevent acute allograft rejection.
Thus, anti-CD40L may exert its effect, at least in part, by
direct T cell ligation (our unpublished data). CD40–
CD40L interactions influence the gradual amplification of
an immune response through the step-wise upregulation of
adhesion and activation molecules. The ability of CD40L
to regulate a response may depend on the availability of ad-
dition coreceptors and/or their cognate ligands as well as
the activation status of the T cell. Teleologically, in the ab-
sence of additional costimulation, regulation of short-term
responses through CD40L ligation could control damage
from a prolonged immune response. An emerging question
in the field of transplantation biology is how treatment reg-
imens that act through the CD28–B7 and CD40L–CD40
pathways exert long-term effects after cessation of treat-
ment. Defining the diverse roles of CD40–CD40L interac-
tions and gaining a better understanding of the molecular
pathways elicited after CD40L ligation will allow clinicians
to identify additional therapeutic targets.
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